Advanced iron oxide nanotheranostics for multimodal and precision treatment of pancreatic ductal adenocarcinoma

• Type of Material: Article
• Authors: Lei Zhu, Emory University; Hui Mao, Emory University; Lily Yang, Emory University
• Language: English
• Date: 2022-04-09
• Publisher: WILEY
• Publication Version: Author Accepted Manuscript (After Peer Review)
• Copyright Statement: © 2024 by John Wiley & Sons, Inc.
• Final Published Version (URL): http://dx.doi.org/10.1002/wnan.1793
• Title of Journal or Parent Work: WILEY INTERDISCIPLINARY REVIEWS-NANOMEDICINE AND NANOBIOTECHNOLOGY
• Volume: 14
• Issue: 4
• Start Page: e1793
• End Page: e1793
• Grant/Funding Information: National Cancer Institute, Grant/Award Numbers: R01CA154846, R01CA202846, U01CA198913
• Keywords: THERANOSTIC NANOPARTICLES; HYPERTHERMIA TREATMENT; MAGNETIC NANOPARTICLES; tumor stroma barrier; Science & Technology - Other Topics; PLASMINOGEN-ACTIVATOR; LIPOSOMAL IRINOTECAN; Research & Experimental Medicine; activation of tumor immune response; theranostic nanoparticles; IN-VIVO; Nanoscience & Nanotechnology; DRUG-DELIVERY; Science & Technology; Medicine, Research & Experimental; Life Sciences & Biomedicine; CONTRAST ENHANCEMENT; targeted and image-guided cancer therapy; IMAGE-GUIDED THERAPY; CANCER; pancreatic cancer
• Research Categories: Health Sciences, Medicine and Surgery; Health Sciences, Oncology; Health Sciences, Radiology

Abstract

Despite current advances in new approaches for cancer detection and treatment, pancreatic cancer remains one of the most lethal cancer types. Difficult to detect early, aggressive tumor biology, and resistance to chemotherapy, radiotherapy, and immunotherapy result in a poor prognosis of pancreatic cancer patients with a 5-year survival of 10%. With advances in cancer nanotechnology, new imaging and drug delivery approaches that allow the development of multifunctional nanotheranostic agents offer opportunities for improving pancreatic cancer treatment using precision oncology. In this review, we will introduce potential applications of innovative theranostic strategies to address major challenges in the treatment of pancreatic cancer at different disease stages. Several important issues concerning targeted delivery of theranostic nanoparticles and tumor stromal barriers are discussed. We then focus on the development of a magnetic iron oxide nanoparticle platform for multimodal therapy of pancreatic cancer, including MRI monitoring targeted nanoparticle/drug delivery, therapeutic response, and tumor re-staging, activation of tumor immune response by immunoactivating nanoparticle and magnetic hyperthermia therapy, and intraoperative interventions for improving the outcome of targeted therapy. This article is categorized under: Nanotechnology Approaches to Biology > Nanoscale Systems in Biology Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease Diagnostic Tools > In Vivo Nanodiagnostics and Imaging.